Midstate Radiology Associates - Radiologists / Radiology Services CT
Search  |  Careers  |  Change font size: A A A

Neurodegenerative Imaging

DAT Scan for Parkinson's Disease

The DAT scan looks at the level of dopamine receptor cells in the brain using a small amount of an iodine based radioactive material. Dopamine is a chemical messenger that transmits messages between nerve cells and muscles. With Parkinson’s disease the dopamine cells degenerate, causing the patient to experience problems with movements, such as walking and dexterity.

What to Expect at a DAT Scan

On arrival, you will be given an oral liquid medicine to block the uptake of the iodine by the thyroid. One hour later, you will be given an intravenous injection of the radioactive tracer. This feels very similar to a blood test and has no side effects. The images are taken about three hours after the injection. You will be asked to lie on your back on a bed with your head in a small cradle. Two cameras will move around your head to create the images but they do not touch the head. The images take about 25 minutes to acquire.

After all the images are completed, the technologist will check them before you go home. We will not be able to give out the result of the study immediately, but a written report will be sent to the referring doctor. There are no side effects from the test. DAT scans are now offered at MidState Medical Center in Meriden.

Alzheimer PET Scan

Alzheimer's disease is a form of dementia that gradually gets worse over time. This disease involves loss of brain function and affects memory, thinking and behavior. Forgetfulness is the first sign of the disease, but most people don't take this symptom seriously. They think that being forgetful is a natural occurrence, especially for older people. This leads to late detection of the disease, and diagnosis when the Alzheimer's has already greatly progressed. Today, most doctors use Alzheimer PET scan as an effective diagnostic tool.

What to Expect at an Alzheimer PET Scan

With the use of the Alzheimer PET scan, brain movements will be evaluated along with the overall sensory functions and coordination. The doctor will diagnose the disease by conducting a physical exam, asking questions about the medical history, and a mental status examination.

With our Alzheimer PET scan service, we assure you that we use the most advanced technology to detect the disease. Though a cure may not still be available for Alzheimer's, through our imaging services, we will help those with Alzheimer's and their family to prepare for the disease. Detection will allow them to be able to cope with the disease better and prepare emotionally and mentally for its effects.

NeuroQuant®: a New MRI Tool that Provides Better Diagnosis and Monitoring of Dementia

NeuroQuant® is software used with MRI that automatically quantifies the volumes of the brain structures affected by Alzheimer’s disease (AD). It can be used to facilitate diagnosis, monitor progression of Alzheimer’s disease and assess the effectiveness of treatment. NeuroQuant® provides age-related brain atrophy reports and compares them to those without the disease.

Clinical Indications for NeuroQuant®

  • Alzheimer’s Disease
  • Dementia
  • Memory loss
  • Mild Cognitive Impairment

Advantages of an MRI with NeuroQuant®

  • Patients 50 years of age or older with a diagnosis of Mild Cognitive Impairment (MCI), which is considered a possible transitional stage towards AD, can have a non-contrast MRI to quantitatively evaluate for increased brain atrophy.
  • Patients can now be monitored to see if the progression is accelerating, and the rate of acceleration, to help in the early detection of the transition from MCI to AD.
  • NeuroQuant® software evaluates the patient’s MRI for brain atrophy and compares the results to a FDA-approved database of people of the same age with healthy brains. It can provide an early warning for patients who have Mild Cognitive Impairment (MCI) and help doctors make a diagnosis and follow the progression of the disease. Studies have found that patients who have a small hippocampus are four times more likely to progress to AD in a few years than patients whose hippocampus is of normal size. The hippocampus in a healthy patient shrinks at about 1% per year, compared to about 5% per year in a person with AD.

NeuroQuant® is a registered trademark of CorTechs Labs, Inc.